Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity.
about
Drug Eluting Stents for Malignant Airway Obstruction: A Critical Review of the LiteraturePharmacogenomics of breast cancer therapy: an updatePrecision targeted therapy of ovarian cancerThe Importance of Patient-Specific Factors for Hepatic Drug Response and ToxicityInfluence of DPYD Genetic Polymorphisms on 5-Fluorouracil Toxicities in Patients with Colorectal Cancer: A Meta-AnalysisInterference in DNA replication can cause mitotic chromosomal breakage unassociated with double-strand breaksAssociation of new deletion/duplication region at chromosome 1p21 with intellectual disability, severe speech deficit and autism spectrum disorder-like behavior: an all-in approach to solving the DPYD enigmaHigh-resolution melting analysis of the common c.1905+1G>A mutation causing dihydropyrimidine dehydrogenase deficiency and lethal 5-fluorouracil toxicity.Screening for 392 polymorphisms in 141 pharmacogenes.Pharmacogenetic testing through the direct-to-consumer genetic testing company 23andMe.Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosingNext-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification.Dihydropyrimidine accumulation is required for the epithelial-mesenchymal transition.Gastric cancer: Classification, histology and application of molecular pathology.53BP1 sensitizes breast cancer cells to 5-fluorouracilUndetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenaseGenotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratio.Actionable pharmacogenetic markers for prediction and prognosis in breast cancer.5-Fluorouracil "Chemowraps" in the Treatment of Multiple Actinic Keratoses: A Norwich ExperiencePhase I study of 5-fluorouracil in children and young adults with recurrent ependymoma.Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase-driven adaptive dosing of 5-FU in patients with digestive cancer.Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy.First-line treatment with hepatic arterial infusion plus capecitabine vs capecitabine alone for elderly patients with unresectable colorectal liver metastasesPersonalized medicine and the clinical laboratory.Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicityScreening of dihydropyrimidine dehydrogenase genetic variants by direct sequencing in different ethnic groups.Hypermutation of DPYD Deregulates Pyrimidine Metabolism and Promotes Malignant Progression.Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity.A review of pharmacogenetics of adverse drug reactions in elderly people.Evaluation of 5-fluorouracil pharmacokinetic models and therapeutic drug monitoring in cancer patients.DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis.Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score.Optimizing initial chemotherapy for metastatic pancreatic cancer.Cancer predisposition syndromes: lessons for truly precision medicine.Pharmacogenetic markers of toxicity for chemotherapy in colorectal cancer patients.Rs895819 in MIR27A improves the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine-associated toxicity.DPYD gene polymorphisms are associated with risk and chemotherapy prognosis in pediatric patients with acute lymphoblastic leukemia.Discovery of novel mutations in the dihydropyrimidine dehydrogenase gene associated with toxicity of fluoropyrimidines and viewpoint on preemptive pharmacogenetic screening in patients.5-Fluorouracil toxicity and dihydropyrimidine dehydrogenase enzyme: implications for practice.Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity.
P2860
Q26766244-B82825F8-EDC0-43BF-B200-52ECF41D58C1Q27006783-EEEA4AE6-B0E6-4215-B114-6BEEF5E28C8FQ28078658-6E04BECA-6B66-4380-85EF-9B31E91467E5Q28080256-0E3A8E67-C2BD-4A73-A367-06315ED7EA96Q28083122-DB6C802A-3E6C-4624-A14E-D95E859499F5Q28485943-555521CC-91BE-45B6-983D-D34CE8594193Q28596636-8B7CA92C-EC15-4FE3-9EC5-BC04A97A3E3FQ33405398-FB171E1B-E43A-42F5-A4B4-D8C18CF8B61EQ33733501-6141C772-F457-4AB4-8AD3-EAB5277C6A39Q33815409-7D1B9C26-B520-4FFB-AC5E-65B05CB47AE7Q34367423-BBED2EC6-3A48-4181-B28B-2FD751CC149CQ34550417-B1DE00BE-FAD0-4BDB-AC0C-E0F9FBC9498DQ34601999-E47AB2E5-6DC2-48BA-9B6C-059E613EBBABQ34642023-D41828F1-EC0D-465B-B3C9-7498B617E494Q34990433-454F522B-40CD-4CD9-841C-4F920C09F6B3Q35585759-8AB8D7C8-6CDC-433C-9574-2E7913BD9E4DQ35743233-3A7FFD9B-87D6-4DF3-92A9-EB6F57FAA11AQ35879741-6FD2FF5A-6623-46C8-8759-BA25500734BCQ36087370-73B04012-10C8-4C82-A05C-3DF58D4F340DQ36250758-68FCD0C7-5753-434D-86A0-C5145A3C6891Q36410237-9363C147-BC68-48AB-A608-1E57FA5B614EQ36709301-670616CB-9D05-4F8B-8414-67F98E6B9CB1Q36843737-7C587FF4-DF00-41F0-BDB2-5455A38AA2EDQ36916966-42E842CF-BCEA-444F-A863-6433ADEE0B1DQ36959145-A67A1363-F982-4E59-BA63-4C0F2017B7ACQ37098042-5D614517-2FCF-41F0-9C47-33073493C4B8Q37258328-F0170DAD-987E-43F4-AFD8-0DB06124C36AQ37595951-DD25E603-F6E5-497E-A01D-BAF181F12465Q38085220-EA1ED620-765C-4D27-A80E-52F67BCA2DC9Q38104743-3898D7FA-A879-4A85-AA39-AF8B18055BE1Q38127715-26276789-F2CF-4F03-ABEB-1A690AB789F0Q38565029-1D14C1B2-93E2-4F37-BD6A-F0705ABB215FQ38900432-04A46131-0F9A-4228-A1AD-CA003341E840Q39012229-55D1FBC8-C77E-44DD-B291-EE417907F8CCQ39566084-E03B70CD-A62B-49E2-AD0B-83F9C7D296D8Q40068183-A1D127B3-00B3-4341-850D-B8003784B0CFQ40805012-EDA95527-9BD2-472F-A57F-C55C3CB2703FQ42018846-0B644C89-A36F-49B6-9B6A-4460F3DC2509Q42045678-5D473122-80FD-41E2-A495-800A79C4446BQ42210747-B73CD595-F171-45C8-83BD-2756318308DA
P2860
Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity.
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Dihydropyrimidine dehydrogenas ...... evere 5-fluorouracil toxicity.
@ast
Dihydropyrimidine dehydrogenas ...... evere 5-fluorouracil toxicity.
@en
Dihydropyrimidine dehydrogenas ...... evere 5-fluorouracil toxicity.
@nl
type
label
Dihydropyrimidine dehydrogenas ...... evere 5-fluorouracil toxicity.
@ast
Dihydropyrimidine dehydrogenas ...... evere 5-fluorouracil toxicity.
@en
Dihydropyrimidine dehydrogenas ...... evere 5-fluorouracil toxicity.
@nl
prefLabel
Dihydropyrimidine dehydrogenas ...... evere 5-fluorouracil toxicity.
@ast
Dihydropyrimidine dehydrogenas ...... evere 5-fluorouracil toxicity.
@en
Dihydropyrimidine dehydrogenas ...... evere 5-fluorouracil toxicity.
@nl
P2093
P2860
P356
P1433
P1476
Dihydropyrimidine dehydrogenas ...... evere 5-fluorouracil toxicity.
@en
P2093
Carlo R Largiadèr
Tanja K Froehlich
Ursula Amstutz
P2860
P304
P356
10.2217/PGS.11.72
P577
2011-09-01T00:00:00Z